Dyadic International EBIT per Share
The EBIT per Share of Dyadic International (DYAI) as of Aug 6, 2026 is -0.22 USD. In the previous year, EBIT per Share was -0.20 USD — a change of 8.83% (lower).
Get this data via API
Financial Data API
EBIT per Share
-0.22USD
YoY
8.83%
Last updated:
EBIT per Share of Dyadic International is 2026 -0.22 USD. EBIT per Share of Dyadic International was 2025 -0.20 USD. It decreases by 8.83% lower compared to the previous year.
Access this data via the Eulerpool API
Dyadic International Stock analysis
What does Dyadic International do? The company Dyadic International Inc was founded in the Netherlands in 1979 and is now headquartered in Jupiter, Florida. The company is a leading global biotechnology company. Dyadic International specializes in the development and production of enzymes and proteins used in the production of foods, agricultural products, pharmaceuticals, and biopharmaceuticals.
The company's business model is based on the use of proprietary technologies and know-how to optimize the production process of enzymes and proteins. Dyadic uses a platform technology called C1, which is based on a mold fungus and allows for the large-scale production of enzymes and proteins. The technology can be used in various ways, providing high flexibility to meet the needs of customers.
One of Dyadic's key sectors is the agricultural industry. The company produces enzymes that increase the efficiency of ethanol production and contribute to the reduction of greenhouse gas emissions. Dyadic also works on the development of enzymes that improve the digestibility of animal feed and contribute to the overall health of animals.
Another important area is the food industry. Dyadic produces enzymes used in the production of foods such as bread, cheese, beverages, and sweeteners. These enzymes improve product properties, such as shelf life and texture, resulting in higher quality and efficiency in production.
Dyadic also operates in the biopharmaceutical industry. The company produces recombinant proteins used in the production of pharmaceuticals. The C1 technology allows for cost-effective production of proteins, particularly beneficial for generic and biosimilar manufacturers.
One example of a Dyadic product in the biopharmaceutical industry is the antibody fragment Dyadic rFVIIa, used in the treatment of bleeding in patients with hemophilia. The C1 technology enables the production of the fragment in large quantities and high purity, contributing to cost-effective production.
Overall, Dyadic has more than 70 partners and customers from various industries worldwide. The company works closely with its customers to develop and produce tailored solutions for their needs. Through the C1 technology and flexibility in application possibilities, Dyadic International Inc is an important partner for companies in different industries that rely on enzymes and proteins.
The main message of the text is that Dyadic International Inc is a leading global biotechnology company specializing in the development and production of enzymes and proteins for various industries. Dyadic International is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Dyadic International stock
EBIT per Share of Dyadic International is -0.22 USD in 2026.
EBIT per Share of Dyadic International changed from -0.20 USD to -0.22 USD, representing a 8.83% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Dyadic International since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Dyadic International
All Key Metrics — Dyadic International
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth